Omnix Medical Secures Significant Series C Funding
Omnix Medical, a pioneering biopharmaceutical company specializing in next-generation anti-infectives, has announced an impressive $25 million raised in its Series C funding round. This funding was co-led by Harel Insurance & Finance and the EIC Fund, along with strong participation from existing investors like Entree Capital, Tal Ventures, Xenia Ventures, and Oriella Limited. Together, these investors are committed to supporting Omnix's ambitious journey towards developing innovative treatments for serious infections.
Addressing Global Health Challenges
The urgency for novel antimicrobials comes as antibiotic-resistant infections continue to pose a significant threat to public health. With this new round of funding, Omnix aims to advance its lead compound, OMN6, through Phase II proof-of-concept studies. This compound is critical for treating infections caused by Gram-negative bacteria, specifically targeting Acinetobacter baumannii—a bacteria notorious for its resistant strains against conventional treatments such as carbapenems and colistin.
Focus on Life-Saving Innovations
Dr. Moshik Cohen-Kutner, CEO of Omnix Medical, expresses optimism about the funding’s potential, stating, “With the support of Harel Insurance & Finance and the EIC Fund, coupled with our existing shareholders, we have the necessary resources to complete essential studies that validate OMN6’s effectiveness. The renewed trust from our investors underscores their confidence in our mission to deliver innovative solutions in anti-infectives.”
Understanding the Role of OMN6
OMN6 stands out as a first-in-class antimicrobial peptide (AMP) with a unique mode of action. Its innovative approach involves disrupting bacterial cell membranes, making it effective across various bacterial genotypes and resistant strains. This mechanism allows OMN6 not only to work quickly but also to maintain its efficacy even in the face of emerging resistance. The compound has already received promising evaluations regarding its safety and stability, which are pivotal for clinical success.
Potential Impact on Treatment Protocols
Dr. Niv Bachnoff, Chief Scientific Officer at Omnix Medical, highlights the unique features of OMN6, stating, “Our AMP’s ability to selectively target bacterial membranes combined with its rapid action significantly reduces the development of resistance. With this recent funding, we are well-positioned to reveal OMN6’s potential to be a game-changer in treating multidrug-resistant infections.”
Omnix Medical’s Vision and Goals
Founded in 2015 at the VLX Ventures incubator, Omnix Medical has dedicated itself to combatting the worldwide crisis of antibiotic resistance. The company has garnered substantial support from the Israeli Innovation Authority, received recognition from the European Union through a competitive EIC Accelerator grant, and has also secured research funding from the U.S. National Institutes of Health (NIH) for its OMN6 program. This backing emphasizes a collaborative effort towards addressing public health emergencies.
Future Prospects and Innovations
Omnix Medical's technology relies on engineered antimicrobial peptides that are designed to selectively target bacterial membranes. OMN6’s rapid action not only enhances its effectiveness but also reduces treatment duration, thereby mitigating the risk of developing resistance, which is a growing concern in modern medicine. The continuous innovation from Omnix positions it as a leader in the biopharmaceutical sector focused on anti-infective solutions.
Corporate Contacts for Further Information
For more insights about Omnix Medical and its offerings, you can reach out to:
Corporate Contacts
Moshik Cohen-Kutner, CEO
Contact Number: +972-50-8698218
Niv Bachnoff, CSO
Contact Number: +972-54-238-6023
Email: contact@omnixmedical.com
Frequently Asked Questions
What is Omnix Medical's recent funding about?
Omnix Medical secured $25 million in Series C funding aimed at advancing its novel antimicrobial therapies, especially focusing on the compound OMN6.
What is OMN6?
OMN6 is a first-in-class antimicrobial peptide designed to disrupt bacterial cell membranes, making it effective against resistant infections.
Why is antibiotic resistance a concern?
Antibiotic resistance leads to infections that are difficult to treat, increasing mortality rates and healthcare costs, making innovative solutions like OMN6 essential.
Who are the key investors in this funding round?
This funding was co-led by Harel Insurance & Finance and the EIC Fund, along with strong support from existing investors like Entree Capital.
What are the expected outcomes from the funding?
The funding will facilitate Omnix to complete Phase II trials for OMN6, enhance regulatory and manufacturing capabilities, and further their development pipeline.
